A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Exclusion Criteria

• •1. Histologically or cytologically confirmed mixed SCLC;
• •2. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
• •3. The toxicity of previous anti-tumor therapy has not been alleviated；
• •4. Have received anti-platelet therapy within 10 days prior to the first dose of the study drugs;
• •5. Evidence and history of severe bleeding tendency;
• •6. History of severe cardiovascular diseases within 6 months;
• •7. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
• •8. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;
• •9. History of alcohol abuse, psychotropic substance abuse or drug abuse;
• •10. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;
• •11. Pregnant or lactating women;
• •12. Other conditions considered unsuitable for this study by the investigator.